Alnylam's Biotherapeutics Unit Could Strike Industry Deals in 'Near Term' | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals expects its biologics unit may soon secure industry deals centering around either drugs in development or ones already on the market, company officials said last week.

"We've really been very encouraged by the robust response to the [establishment] of this initiative," Stuart Pollard, Alnylam's vice president of scientific and business strategy, said during a conference call held last week to discuss the company's first-quarter financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.